C1QBP and glioma: In conclusion, our study provided evidence of specific surface expression of p32 in gliomas, and the potent antitumor and anti-angiogenic activity of p32-specific CAR T cells against glioma and tumor-associated and derived endothelial cells, indicating it may be of relevance for the treatment of glioma patients.